Late last week the Drug Enforcement Administration (DEA) announced that CBD would be taken off of Schedule I and moved to Schedule 5.This sounds like a huge victory on the surface. The truth is that this does not apply to all forms of CBD; the DEA’s new ruling only applies to CBD drugs that have been approved by the FDA. so far the DEA’s ruling would only apply to one drug: Epidiolex.
Epidiolex,which is used to treat seizures, is the only CBD drug that has been approved by the FDA so far, and as such is the only CBD compound that would fall under the DEA’s ruling. Other CBD compounds, such as the ones most people would get from the dispensary, one can presume are still in that legal grey area.
Immediately in response to this news stock for GW Pharmaceuticals, the company that developed Epidiolex, went up considerably. This is of course to be expected. GW can now corner the market on CBD drugs because they are the only ones allowed to sell them! GW will now be able to control the price of Epidiolex, which they’ve said they would sell for 32,000 for a year’s worth of treatment. This is well out of reach for the vast majority of people who could use this drug.
Of course, Epidiolex will not be the only FDA approved CBD drug forever; other drugs will follow. The DEA’s ruling is is still marks a landmark decision. The DEA has never before moved any kind of cannabis from Schedule I and them doing this could be a sign of things to come.
Source: Hemp Industry Daily
Image Source: Leafly
Is this ultimately a good, albeit disappointing decision by the DEA, or does it spell disaster for CBD patients? Tell us your thoughts in the comments below!